| Revenue growth | 10.6% YoY in Q3 FY26 |
|---|---|
| Margins | Gross margin 58.1% (up 184bps); EBITDA margin 21.3% (up 217bps) |
| Order book | US order book exceeds $220 million |
| Demand visibility | Strong US order book and seasonal uptick in cough/cold |
| Management confidence | High; optimistic on US market dynamics and UK recovery |
Growth
Q3 Revenue grew 10.6% YoY; PAT increased 8.2% to ₹113.7cr. 9M FY26 Revenue up 9.4% YoY.
Outlook
Targets ₹4,000cr revenue by FY28; R&D spend 2.5-3% of sales; actively pursuing European acquisitions; Capex ₹50-60cr.
Risks
Price erosion in UK/US Rx segments; macroeconomic challenges in ROW markets; rising employee costs due to new labor codes.
Earnings Call filed with BSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹325.00
- Market cap
- ₹14,728 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.5×Sector 47.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Annual General Meeting
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Other Announcement
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Marksans Pharma Investor Presentation: Key Takeaways
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
- Call
- Guides 20% growth
Marksans Pharma Q1 FY27 Results: Net Profit ₹159.4 Cr, Up 173.9% YoY
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹159.4 Cr · +173.9% YoY